Q-LINE BIOTECH LIMITED vs TORRENT PHARMACEUTICALS L
A side-by-side comparison of Q-LINE BIOTECH LIMITED (QLINE) and TORRENT PHARMACEUTICALS L (TORNTPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, Q-LINE BIOTECH LIMITED leads QLINE vs TORNTPHARM on 8 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation22
- Profitability31
- Growth20
- Size & financial health13
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
EvenHow expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
QLINE takes 3/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
QLINE takes 2/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
TORNTPHARM takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company has a good return on equity (ROE) track record: 3 Years ROE 21.7%"]
- − ["Stock is trading at 5.70 times its book value", "Though the company is reporting repeated profits, it is not paying out dividend"]
- + ["Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 67.6%"]
- − ["Stock is trading at 20.67 times its book value", "Company has a high debt to equity ratio of 1.79."]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.